Technical Trend Shift and Price Performance
On 25 Nov 2025, Alembic Pharmaceuticals Ltd. was downgraded from a Hold to a Sell rating, with its Mojo Score falling to 37.0, indicating a cautious stance for investors. The stock, classified as a small-cap within the Pharmaceuticals & Biotechnology sector, closed at ₹718.85 on 2 Jun 2026, down from the previous close of ₹735.10. This decline of 2.21% on the day is consistent with the broader technical signals pointing towards bearish momentum.
Price volatility remains evident, with the day’s high at ₹737.35 and low at ₹716.00, while the stock trades significantly below its 52-week high of ₹1,107.80, highlighting a substantial retracement. The 52-week low stands at ₹635.30, indicating that while the stock is closer to its lower range, it has not breached critical support levels yet.
Moving Averages and Momentum Indicators
The daily moving averages have turned bearish, signalling that the short-term trend is negative. This is corroborated by the Relative Strength Index (RSI) on the weekly chart, which is also bearish, suggesting that the stock is experiencing downward pressure and may be oversold in the near term. However, the monthly RSI currently shows no clear signal, indicating some uncertainty in the longer-term momentum.
The Moving Average Convergence Divergence (MACD) presents a mixed picture: mildly bullish on the weekly timeframe but bearish on the monthly. This divergence suggests that while short-term momentum may attempt to stabilise or recover, the longer-term trend remains under pressure. The KST (Know Sure Thing) indicator aligns with this view, mildly bullish weekly but bearish monthly, reinforcing the notion of short-term attempts at recovery amid a prevailing downtrend.
Bollinger Bands and Volume Trends
Bollinger Bands on both weekly and monthly charts are bearish, indicating that price volatility is skewed towards the downside and the stock is trading near the lower band. This often signals increased selling pressure and potential continuation of the downtrend unless a strong reversal catalyst emerges.
On-Balance Volume (OBV) readings show no clear trend on weekly or monthly charts, suggesting that volume is not confirming either buying or selling pressure decisively. This lack of volume confirmation may imply that the current price moves are driven more by sentiment than by strong institutional participation.
Our current Stock of the Month is out! This Large Cap from Automobiles - Passenger Cars emerged as the single best opportunity from our elite universe. Get the details now!
- - Current monthly selection
- - Single best opportunity
- - Elite universe pick
Comparative Returns and Market Context
When analysing Alembic Pharmaceuticals’ returns relative to the Sensex, the stock has underperformed across most timeframes. Over the past week, the stock declined by 5.77% compared to the Sensex’s 2.90% fall. The one-month return shows a similar pattern with a 4.72% drop versus the Sensex’s 3.44% decline. Year-to-date, Alembic’s return is down 15.25%, lagging the Sensex’s 12.85% decrease.
More concerning is the one-year performance, where Alembic Pharmaceuticals has fallen 29.20%, significantly underperforming the Sensex’s 8.82% loss. Even over a five-year horizon, the stock has declined 23.88%, while the Sensex has gained 43.00%, highlighting persistent challenges for the company’s share price relative to the broader market.
However, the three-year and ten-year returns tell a more nuanced story. Alembic has delivered a 31.17% gain over three years, outperforming the Sensex’s 18.96% return, and a 32.28% gain over ten years, though this is well below the Sensex’s 178.01% surge. These figures suggest that while the company has had periods of relative strength, recent trends have been decidedly negative.
Dow Theory and Broader Technical Signals
According to Dow Theory, the weekly trend is mildly bullish, indicating some resilience in the short term. However, the monthly trend shows no clear direction, reinforcing the mixed signals from other indicators. This ambiguity suggests that investors should exercise caution and closely monitor upcoming price action for confirmation of trend direction.
The overall technical summary has shifted from mildly bearish to bearish, reflecting a deterioration in momentum and increasing downside risk. This shift is consistent with the downgrade in the Mojo Grade from Hold to Sell, signalling that the stock’s technical health has weakened materially.
Considering Alembic Pharmaceuticals Ltd.? Wait! SwitchER has found potentially better options in Pharmaceuticals & Biotechnology and beyond. Compare this small-cap with top-rated alternatives now!
- - Better options discovered
- - Pharmaceuticals & Biotechnology + beyond scope
- - Top-rated alternatives ready
Implications for Investors
Given the current technical landscape, Alembic Pharmaceuticals Ltd. appears to be in a phase of weakening momentum with increased downside risk. The bearish signals from daily moving averages, weekly RSI, and Bollinger Bands suggest that the stock may continue to face selling pressure in the near term. The divergence between weekly and monthly MACD and KST indicators indicates potential short-term attempts at recovery, but these are unlikely to reverse the broader negative trend without significant fundamental catalysts.
Investors should weigh these technical signals alongside the company’s fundamental outlook and sector dynamics. The Pharmaceuticals & Biotechnology sector often experiences volatility due to regulatory developments, product approvals, and competitive pressures, which can influence price momentum. In Alembic’s case, the downgrade to a Sell rating and the small-cap classification further underscore the need for caution.
For those holding positions, it may be prudent to monitor support levels near the 52-week low of ₹635.30 and watch for any volume-backed reversals. New investors might consider waiting for clearer signs of trend stabilisation or exploring alternative opportunities within the sector that exhibit stronger technical and fundamental profiles.
Conclusion
Alembic Pharmaceuticals Ltd. is currently navigating a challenging technical environment marked by bearish momentum and a recent downgrade in its Mojo Grade. The mixed signals from various technical indicators highlight short-term volatility but a prevailing downtrend in the medium to long term. Comparative underperformance against the Sensex across multiple timeframes adds to the cautious outlook. Investors should remain vigilant and consider the broader market context and sector-specific factors before making investment decisions.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
